Insmed (INSM) announced that it will present seven abstracts from across its late-stage portfolio at the European Respiratory Society, ERS, 2025 Congress, taking place September 27 – October 1, 2025, in Amsterdam. Notably, data from the Phase 2 trial in treprostinil palmitil inhalation powder in patients with pulmonary arterial hypertension will be highlighted in the Congress’s Abstracts Leading to Evolution in Respiratory Medicine Trials session, which showcases important, late-breaking clinical data from all respiratory disease areas. In addition, presentations include three prespecified subgroup analyses from the Phase 3 ASPEN trial evaluating the efficacy and safety of brensocatib, including Japanese patient data, as well as Health Outcomes and Economic Research from The Health Improvement Network database in France and the United Kingdom in patients with non-cystic fibrosis bronchiectasis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Promising Market Potential for Insmed’s Brensocatib Drives Buy Rating
- Insmed price target raised to $172 from $125 at Guggenheim
- Insmed’s Strategic Advancements and Market Potential: A Buy Recommendation
- Optimistic Buy Rating for Insmed: TPIP’s Potential in the IPF Market
- Cautious Hold Rating on Insmed Amid Positive IPF Trial Results and Awaited Strategic Clarity